Company: DNLI
Filing Date: 2025-04-17
Form Type: DEF 14A
Source: 0001714899-25-000087
Chunk: 29

Company: Denali Therapeutics Inc.
Filing Date: 2025-04-17
Form: DEF 14A
Chunk 29
---
 non-employee director will have until the later of the deadline in the prior sentence or two years from the date of such increase to satisfy the portion of the requirement attributable to the retainer increase. Until a non-employee director has satisfied the applicable level of ownership, and during any period in which the director ceases to satisfy the applicable level of ownership, such director may generally not sell or transfer more than fifty percent (50%) of the net shares received from any equity award granted to the non-employee director or derived from such director’s other direct holdings. At the discretion of our compensation committee, the stock ownership requirements may be waived for non-employee directors joining our board of directors from government, academia, or similar professions and may be temporarily suspended if the requirements would create severe hardship or prevent the non-employee director from complying with a court order.

<div align='center'>-20-</div>

#### Role of the Board in Risk Oversight
One of the key functions of our board of directors is informed oversight of our risk management process. Our board of directors does not have a standing risk management committee, but rather administers this oversight function directly through the board of directors as a whole, as well as through its standing committees that address risks inherent in their respective areas of oversight.

A summary of the key areas of risk oversight responsibility of our board of directors and each of its committees is set forth below:

| Board or Committee                            |     | Area of Risk Oversight                                                                                                                                                                     |
| Board                                         |     | *Monitoring and assessing strategic risks                                                                                                                                                  
 *Research and development activities, clinical development, drug safety and intellectual property                                                                                          
 *Risk management policies, guidelines and practices implemented by Company management                                                                                                      |
| Audit Committee                               |     | *Financial, accounting, disclosure and corporate compliance, including the steps management has taken to monitor and control these exposures, and oversight of internal and external audit 
 *Information security and cybersecurity risks                                                                                                                                              
 *Guidelines and policies with respect to risk assessment and risk management                                                                                                               
 *Compliance with legal and regulatory requirements                                                                                                                                         
 *Related party transactions                                                                                                                                                                |
| Compensation Committee                        |     | *Compensation policies and practices, including whether such policies and practices balance risk-taking and rewards in an appropriate manner as discussed further below                    |
| Corporate Governance and Nominating Committee |     | *Effectiveness of corporate governance guidelines, including board succession, director independence and potential conflicts of interest                                                   |

#### Compensation Risk Assessment
The Compensation Discussion and Analysis (CD&A) section of this Proxy Statement describes our compensation policies,